STATUS
Ongoing project
STARTING/ENDING
2023 – 2025
FUNDING
Public; European Research Council
Proof of Concept Grant
STREMBLE’S ROLE
Commercial Partner
STREMBLE’S ROLE
In partnership with University of Milan, Stremble will advance the analytical methods of mutation signatures to develop a novel diagnostic tool for high-risk SMM. Stremble will establish an IPR strategy and commercialisation plan for future development of the tool.
- Bioinformatics analysis
- IPR strategy
- Market analysis
- Commercialisation plan
ABOUT MYELOMA-RISK PROJECT
Mutation signature analysis of DNA sequencing data has been developed by the University of Milan to identify and characterise the process of clonal evolution and disease progression in asymptomatic multiple myeloma (MM). However, these state-of-the-art methods are based on whole genome and whole exome DNA sequencing which are prohibitively expensive to use for routine clinical use.
The aim of this Proof of Concept (PoC) project is to advance a novel diagnostic methodology using a modified mutation signature analysis method to identify high-risk smoldering multiple myeloma (SMM) patients at a cost that makes it sustainable based on a health technology assessment. This will enable future routine diagnostic testing that will identify at risk patients at an earlier stage and, therefore, facilitate the development of new treatments and ultimately improve patient outcomes.
The PoC will establish a complete development strategy with a market analysis of the potential, feasibility and risks of bringing such a test to market that will act as the business roadmap for the following years. The outcome of the PoC will be an IPR strategy for the long-term development and exploitation of the novel diagnostic procedure, as well as a framework for future commercial development.
VISIT PROJECT WEBSITE
CONSORTIUM
